Response to: “Comment on ‘Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry’” - 31/03/21

Angela L. Bosma, MD ^{a, ⁎} , Linde E.M. de Wijs, MD ^b, Michel H. Hof, PhD ^c, Beau R. van Nieuwenhuizen, MD ^a, Louise A.A. Gerbens, MD, PhD ^a, Maritza A. Middelkamp-Hup, MD, PhD ^a, DirkJan Hijnen, MD, PhD ^b, Phyllis I. Spuls, MD, PhD ^a

^a Department of Dermatology, Amsterdam Public Health, Immunity and Infections, Amsterdam University Medical Centers, Location Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands 

^b Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands 

^c Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam University Medical Centers, location Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands 

^∗Correspondence to: Angela L. Bosma, MD, Department of Dermatology, Amsterdam Public Health, Immunity and Infections, Amsterdam University Medical Centers, location Academic Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam 1105 AZ, the NetherlandsDepartment of DermatologyAmsterdam Public HealthImmunity and InfectionsAmsterdam University Medical Centerslocation Academic Medical CenterUniversity of AmsterdamMeibergdreef 9Amsterdam1105 AZthe Netherlands

Le texte complet de cet article est disponible en PDF.